The method of claim 85 wherein the composition is daptomycin that is substantially free of anhydro-daptomycin and substantially free of β-isomer of daptomycin.

The method of claim 85 wherein the composition is daptomycin that is essentially free of each of impurities 1 to 14 defined by peaks 1-14 shown in <figref idref="DRAWINGS">FIG. 12</figref>.

The composition of claim 97, wherein the size selection technique is ultrafiltration or size exclusion chromatography.

The method according to claim 48 wherein the dose is 4 mg/kg.

The method according to claim 48 wherein the dose is 6 mg/kg.

The method according to claim 14, wherein the dose is 4 mg/kg administered once every 24 hours.

The method according to claim 14, wherein the dose is 6 mg/kg administered once every 24 hours.

The method according to claim 33, wherein the dose is 4 mg/kg.

The method according to claim 33, wherein the dose is 6 mg/kg.

The pharmaceutical composition of claim 22, wherein the daptomycin is obtained from the daptomycin aggregate by a method comprising the steps of a) filtering the daptomycin aggregate under conditions in which the daptomycin aggregate is retained on the filter; and b) collecting the daptomycin aggregate. view more

The composition of claim 52, wherein a) the composition is a lyophilized powder compatible with a pharmaceutically acceptable carrier for the treatment of an infection by a daily intravenous dose of 1 to 12 mg/kg of the daptomycin in a reconstituted solution of the lyophilized powder in the pharmaceutically acceptable carrier; and b) the daptomycin has a purity of about 94 to 96% relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12, the daptomycin having less than 1% of the lactone hydrolysis product of daptomycin, less than 4% anhydro daptomycin and less than 4% of the β-isomer of daptomycin. view more